Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Meyer

Psychiatry Paducah, KY Medical Doctor

NPI 1811957459 CMS profile 218431

100 Fountain Ave, Suite # 301, Paducah, KY 42001

Open in the dashboard

General payments

$16,882

349 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Meyer of Paducah, KY is reported in the CMS Open Payments database as having received $16,882 across 349 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $921 42
2024 General $2,000 83
2023 General $1,538 113
2022 General $5,001 42
2021 General $396 22
2020 General $208 13
2019 General $6,818 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Meyer
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to David Meyer were reported at $921. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year David Meyer Psychiatry median Middle half National median
2019 $6,818 $184 $59–$605 $163
2020 $208 $119 $36–$372 $114
2021 $396 $143 $43–$576 $132
2022 $5,001 $153 $50–$590 $149
2023 $1,538 $170 $56–$651 $160
2024 $2,000 $179 $57–$673 $164
2025 $921 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sunovion Pharmaceuticals Inc. $6,571 21 payments
  2. Otsuka America Pharmaceutical, Inc. $4,281 14 payments
  3. AbbVie, Inc. $1,237 76 payments
  4. ITI, Inc. $1,052 55 payments
  5. Teva Pharmaceuticals USA, Inc. $672 25 payments
  6. Axsome Therapeutics, Inc. $639 36 payments
  7. Tris Pharma Inc $309 14 payments
  8. Neurocrine Biosciences, Inc. $287 5 payments
  9. Vanda Pharmaceuticals Inc. $266 7 payments
  10. Supernus Pharmaceuticals, Inc. $222 32 payments
  11. Other $1,346 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,063 9 payments
  2. Food and Beverage $6,685 337 payments
  3. Education $76 2 payments
  4. Travel and Lodging $58 1 payment
Products named General payments · program years 2019–2025
  1. LATUDA $6,571 21 payments
  2. REXULTI $4,260 12 payments
  3. VRAYLAR $1,161 73 payments
  4. CAPLYTA $844 46 payments
  5. Auvelity $625 35 payments
  6. Dyanavel XR $309 14 payments
  7. UZEDY $305 15 payments
  8. Austedo XR $302 7 payments
  9. INGREZZA $287 5 payments
  10. FANAPT $266 7 payments
  11. Other $2,977 156 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 71 drugs

Part D claims

5,896

Median for Psychiatry: 574

Drug cost

$697,016

Median for Psychiatry: $27,624

Branded share of claims

27.8%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Xr Deutetrabenazine Brand 25 $169,770
Vraylar Cariprazine Hcl Brand 87 $138,141
Ingrezza Valbenazine Tosylate Brand 12 $94,313
Caplyta Lumateperone Tosylate Brand 28 $53,510
Rexulti Brexpiprazole Brand 18 $34,308
Abilify Maintena Aripiprazole Brand 11 $31,476
Auvelity Dextromethorphan Hbr/Bupropion Brand 21 $22,293
Aripiprazole Generic 192 $21,118
Trintellix Vortioxetine Hydrobromide Brand 26 $19,754
Latuda Lurasidone Hcl Brand 11 $17,693

The 10 drugs with the highest cost, of 71 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$67,745

Medicare's payments for the services billed

Medicare patients

180

Average age 69

Services billed

1,106

121 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Arthritis 55%
Diabetes 34%
Chronic kidney disease 27%
Ischemic heart disease 22%
COPD 19%
Heart failure 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $535
$535 87 —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $258
$258 — —
Auvelity
  • Axsome Therapeutics, Inc. $247
$247 21 —
FANAPT
  • Vanda Pharmaceuticals Inc. $189
$189 — —
Dyanavel XR
  • Tris Pharma Inc $168
$168 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

349 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record